The High Court of Judicature at Madras has issued a significant interim injunction against Med Manor Organics and DM Pharma Private Limited, effectively halting the manufacturing, marketing, and distribution of their pharmaceutical product branded as “ZINCOMED.” This judicial intervention, delivered by Justice P.B. Balaji, follows a commercial suit filed by Chennai-based Apex Laboratories Pvt Ltd, which alleged that the respondents were infringing upon its long-standing “ZINCOVIT” trademark, a widely recognized brand in the vitamin supplement sector.

The court’s decision arrives as a critical protection for Apex Laboratories, which demonstrated to the Bench that it has been a prominent player in the pharmaceutical industry since its incorporation in 1978. According to the court records, the company successfully registered the “ZINCOVIT” trademark in 1988 and commenced its commercial usage in 1990. The plaintiff submitted evidence highlighting an impressive sales turnover exceeding Rs. 320 crores for the ZINCOVIT product line in the last financial year, underscoring the brand’s immense market footprint and established consumer base.

Upon examining the comparative evidence presented by the legal counsel for the plaintiff, Justice Balaji noted a clear visual similarity between the two product lines. The court observed that the defendants appeared to have imitated not only the phonetically similar trademark but also the specific artistic presentation of the applicant’s product. “Prima facie, I am able to see that a similar style of carton has been copied and the font style has also been copied by the respondents/defendants,” the court stated in its findings. This assessment formed the basis for the conclusion that there is a significant likelihood of confusion for the general public, a factor central to the laws governing trademark infringement and passing off.

Protecting Brand Equity and Consumer Trust

The legal battle stems from allegations that the respondents were capitalizing on the reputation and goodwill painstakingly built by Apex Laboratories over several decades. Apex contended that the respondents had filed for the registration of “ZINCOMED” under a “proposed to be used” basis, signaling an intent to leverage the brand recognition associated with the plaintiff's products. The court acknowledged that the harm inflicted by such infringement is not merely restricted to financial losses but encompasses the degradation of a brand’s hard-earned reputation.

In view of the urgency of the matter, the court found merit in the plaintiff's request to dispense with the mandatory pre-institution mediation usually required under Section 12A of the Commercial Courts Act, 2015. The court emphasized that the applicant had acted with dispatch upon discovering the alleged infringing activities in August 2026, thereby justifying the immediate grant of interim relief. The judge remarked that failing to restrain the defendants at this juncture would result in irreparable loss and hardship, as the unauthorized use of a similar mark threatened the proprietary rights and established market identity of the plaintiff.

Judicial Scrutiny of Market Conduct

The court further noted that the applicant had established a robust prima facie case, bolstered by its registered trademark and copyright under No. A 115854/2017. The defendants were restrained from utilizing any labels, artistic works, or packaging that served as a substantial reproduction of the applicant’s registered design. This prohibition extends to all facets of the trade, including the distribution, display, and advertisement of ZINCOMED products that share the disputed color schemes, layout, or typography associated with ZINCOVIT.

The order also requires the applicant to adhere to the provisions outlined in Order XXXIX Rule 3(a) of the Code of Civil Procedure, which mandates the filing of a compliance affidavit with the court. This procedural step ensures that the defendants are properly notified and that the interim directions are communicated effectively.

Current Status and Next Steps

By granting this injunction, the High Court has effectively halted the respondents’ ability to circulate the ZINCOMED product in the marketplace pending the final resolution of the suit. This order serves as a stern reminder of the judiciary's role in maintaining market integrity, particularly in the pharmaceutical sector where consumer trust is paramount.

The court has issued formal notices to the respondents to appear for further proceedings, and the matter has been listed for a hearing on January 8, 2027. Until that date, the respondents—including their partners, agents, distributors, and stockists—are legally bound to refrain from any activity that would constitute an infringement of Apex Laboratories' registered intellectual property. As the litigation moves forward, the focus will remain on the long-term impact of this infringement and the final determination of the plaintiff’s claims regarding the dilution of its brand value. For now, the injunction stands as a temporary but decisive safeguard for the integrity of the ZincoVit brand.